Cipla gets 8 inspectional observations from USFDA for Pithampur facility

20 Feb 2023 Evaluate

The United States Food and Drug Administration (USFDA) has conducted a current Good Manufacturing Practices (cGMP) inspection at Cipla’s Pithampur manufacturing facility from February 6 - 17, 2023. On conclusion of the inspection, the Company has received 8 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1312.85 -2.00 (-0.15%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×